Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6006 clinical trials
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

multiple myeloma
measurable disease
  • 0 views
  • 05 Aug, 2020
A Multicentre Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.

cancer
multiple myeloma
bortezomib
  • 0 views
  • 16 Feb, 2024
  • 1 location
T Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse

Safety and Effectiveness of Donor T Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

  • 0 views
  • 05 Aug, 2020
A Cognitive Behavioral Therapy Group Intervention to Increase HIV Testing and PrEP Use Among Latinx Sexual Minority Men

This study consists of a randomized controlled trial (RCT) of a multi-session cognitive behavior therapy (CBT) group intervention that aims to improve HIV outcomes by increasing adaptive, effective coping responses to stigma from intersectional identities related to ethnicity, immigration status, sexual minority identity, HIV status, and PrEP use among Latinx …

hiv test
cognitive therapy
behavior therapy
behavior modification
  • 0 views
  • 16 Feb, 2024
  • 1 location
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

schwartz
neurofibroma
cataract
crizotinib
neutrophil count
  • 0 views
  • 16 Feb, 2024
  • 17 locations
Connexin Genotypes in Cystic Fibrosis

Background: There is wide variety in lung disease phenotype for the delta F508 (homozygous) genotype. A leukocyte driven inflammation is most important for the pathogenesis of pulmonary disease in CF. Blood cytokines correlate negatively with pulmonary function in delta F508 homozygous patients. Gap junction proteins might be of importance for …

pulmonary function test
cystic fibrosis
lung transplant
forced expiratory volume
prednisone
  • 0 views
  • 16 Feb, 2024
  • 3 locations
Balloon Lithoplasty for Preparation of Severely Calcified Coronary Lesions

Severely calcified coronary stenoses are difficult to treat with percutaneous coronary intervention (PCI) using current techniques and there is little specific evidence on how to best treat these cases. It is hypothesized that balloon lithoplasty is superior to conventional balloons for lesion preparation of severely calcified coronary lesions before stent …

ischemia
percutaneous coronary intervention
antiplatelet therapy
coronary disease
heart disease
  • 0 views
  • 16 Feb, 2024
  • 6 locations
A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022.

primary cns lymphoma
b-cell lymphoma
lymphoma
diffuse large b-cell lymphoma
  • 0 views
  • 05 Aug, 2020
Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma

This study is a open-lable, , single center, phase II clinical study. Target population is patients with locally resectable osteosarcoma. Study objective is to compare the efficacy and safety of camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate in study population in China. Camrelizumab is a humanized anti-PD1 IgG4 …

substance abuse
resectable osteosarcoma
ifosfamide
adriamycin
methotrexate
  • 0 views
  • 16 Feb, 2024
  • 1 location
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

The purpose of this study is to determine if it is possible to give CPI-613 with the drug Bendamustine for 2 days every 28 days without causing severe side effects. In addition, this study will also test the safety of CPI-613 when given in combination with Bendamustine.

cutaneous t-cell lymphoma
psoralen
absolute neutrophil count
hodgkin's disease
renal function test
  • 0 views
  • 16 Feb, 2024
  • 1 location